STOCK TITAN

Theratechnologies to Present at the H.C. Wainwright 5th Annual Nash Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer, will participate at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021 at 4:30 p.m. ET.

A live webcast of Dr. Marsolais’ presentation will be available through the ‘Events’ section of the Company’s investor relations website and will be archived for 90 days.

About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

For investor and media inquiries:
Leah Gibson
Senior Director, Investor Relations
communications@theratech.com
617-356-1009


Theratechnologies Inc. Common

NASDAQ:THTX

THTX Rankings

THTX Latest News

THTX Stock Data

61.61M
34.20M
6.29%
50.89%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.